Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
| Status: | Archived |
|---|---|
| Conditions: | Colorectal Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2010 |
| End Date: | July 2012 |
A Phase I Study of Everolimus (mTOR Inhibitor) and OSI-906 (Dual IGFR and IR Tyrosine Kinase Inhibitor) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of the
combination of OSI-906 and everolimus for the treatment of patients with refractory
metastatic colorectal cancer.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials